| 货号 | 10618-5mg |
| 描述 | PLX4032 is an orally bioavailable, ATP-competitive inhibitor of mutant V600E and wild type B-Raf kinases (IC50s = 31 and 100 nM, respectively).1 It inhibits cell proliferation in a variety of cell lines expressing B-Raf V600E and synergizes strongly with taxol, vinblastine, and oxaliplatin in inhibiting the proliferation of B-RafV600E transformed cancer cells.1 PLX4032 is effective against the growth of tumors bearing the B-Raf V600Emutation.2,3,4,5 |
| 别名 | RG-7204;Ro 51-85426;Vemurafenib; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Khazak, V.,Astsaturov, I.,Serebriiskii, I.G., et al. Selective Raf inhibition in cancer therapy. Expert Opin.Ther.Targets 11(12), 1587-1609 (2007). 2.Flaherty, K.T.,Puzanov, I.,Kim, K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine 363(9), 809-819 (2010). 3.Bollag, G.,Hirth, P.,Tsai, J., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010). 4.Coffee, E.M.,Faber, A.C.,Roper, J., et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer. Clinical Cancer Research 19(10), 2688-2698 (2013). 5.Huang, T.,Karsy, M.,Zhuge, J., et al. B-Raf and the inhibitors: From bench to bedside. J.Hematol.Oncol. 6, 1-9 (2013). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 489.9 |
| 分子式 | C23H18ClF2N3O3S |
| CAS号 | 918504-65-1 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |